Comparing Stem Cells from Marrow and Blood for Myeloma Treatment
Author Information
Author(s): N Raje, R Powles, C Horton, B Millar, V Shepherd, G Middleton, S Kulkarni, T Eisen, J Mehta, S Singhal, J Treleaven
Primary Institution: Royal Marsden Hospital
Hypothesis
Is there a difference in outcomes between autologous bone marrow transplants and peripheral blood stem cell transplants in multiple myeloma patients?
Conclusion
Patients receiving peripheral blood stem cell transplants had faster recovery and shorter hospital stays, but overall survival and relapse rates were similar to those receiving bone marrow transplants.
Supporting Evidence
- Platelet recovery was significantly faster in PBSCT patients (19 days) compared to ABMT patients (33 days).
- The median overall survival at 3 years was 76.9% for ABMT and 85.3% for PBSCT.
- PBSCT patients spent fewer days in the hospital (median 20 days) compared to ABMT patients (median 27 days).
- The complete remission rate was 84% for ABMT and 70% for PBSCT, but this difference was not statistically significant.
Takeaway
This study looked at two types of stem cell transplants for treating myeloma. One type helped patients recover faster and stay in the hospital less time, but both types worked about the same in keeping patients healthy long-term.
Methodology
Patients received either autologous bone marrow transplants or peripheral blood stem cell transplants after chemotherapy, and their recovery and outcomes were compared.
Limitations
The study was conducted at a single center, which may limit the generalizability of the results.
Participant Demographics
Patients were new and untreated multiple myeloma patients under the age of 70, with a median age of 50 years.
Statistical Information
P-Value
0.0015 for platelet recovery, 0.00001 for hospital stay duration
Confidence Interval
95% CI 60-93% for ABMT, 95% CI 72-99% for PBSCT
Want to read the original?
Access the complete publication on the publisher's website